SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Meta Expands AI Training With Employee Activity Tracking Tools 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
DENVER, May 24, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen M. Deitsch, Senior Vice President, Chief Financial Officer and Treasurer will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017, at 4:00 p.m. EDT.
A live webcast of the presentation and copies of the materials presented can be accessed via BioScrip’s Investor Relations website at https://www.bioscrip.com/investors or through the following link http://wsw.com/webcast/jeff105/bios.
About BioScrip
BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Stephen Deitsch Chief Financial Officer & Treasurer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
